Results 41 to 50 of about 66,892 (264)

Protective effect of aqueous extract of Pleurotus eous against Dalton's lymphoma ascites tumor in mice

Journal of Agriculture and Food Research, 2023
The antitumor efficacy of Pleurotus eous aqueous extract (PEAE) was investigated both in vitro and in vivo. The MTT test was used to determine in vitro cytotoxicity against the Dalton's Lymphoma Ascites (DLA) cell line.
Vadivukkarasi Sasikumar, Sudha Govindan, Gayathri Rajendran, Archana Rajendran, Prasanna Ramani, Mirian Pateiro, José M. Lorenzo   +6 more
doaj   +1 more source

High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines. [PDF]

, 2016
Hundreds of genetically characterized cell lines are available for the discovery of genotype-specific cancer vulnerabilities. However, screening large numbers of compounds against large numbers of cell lines is currently impractical, and such experiments
A Basu, Alykhan F Shamji, Andrew Crenshaw, Andrew L Kung, Aristotle M Mannan, Aviad Tsherniak, Bang Wong, Barbara A Weir, Bradley R Taylor, C Ditchfield, Channing Yu, D Peck, E Comer, Griselda Metta Yvone, J Barretina, J Du, JM Korn, Joshua Z Gould, JP Koivunen, JT Lowe, Kenneth N Ross, KT Flaherty, LA Marcaurelle, Levi A Garraway, M Carmena, Melissa A Marton, MI Davis, Michael A Foley, Michelle A Palmer, MJ Garnett, MK Muellner, ML Sos, MW Karaman, NC Turner, OD Abaan, Pablo Tamayo, PD Andrews, SL Schreiber, SM Wilhelm, Stuart L Schreiber, SV Sharma, Todd R Golub, U McDermott, Wendy Winckler, XD Zhang, Yan-Ling Zhang   +45 more
core   +2 more sources

Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo

PLoS ONE, 2023
Metastatic colorectal cancer (mCRC) is the second leading cause of cancer deaths in the United States. More than 50% of patients with mCRC harbor mutations of the oncogenic driver RAS (KRAS or NRAS).
Fan Fan, Susmita Ghosh, Reid Powell, Jason Roszik, Yongsun Park, Mary Sobieski, Alexey Sorokin, Clifford Stephan, Scott Kopetz, Lee M. Ellis, Rajat Bhattacharya   +10 more
doaj   +2 more sources

Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer [PDF]

, 2017
SRC tyrosine kinase is frequently overexpressed and activated in late-stage, poor prognosis ovarian tumours, and preclinical studies have supported the use of targeted SRC inhibitors in the treatment of this disease.
El-Helali, Aya, Kennedy, Richard D., McCabe, Nuala, McGivern, Niamh, Mcneish, Iain A., Mullan, Paul, Paul Harkin, D   +6 more
core   +2 more sources

Uso de teste de químio-sensibilidade para escolha da quimioterapia adjuvante no câncer gástrico avançado

Revista do Colégio Brasileiro de Cirurgiões
OBJETIVO: Introduzir e familiarizar em nosso meio o uso do teste de químio-sensibilidade MTT avaliando a ação de agentes quimioterápicos sobre células tumorais de 30 doentes com câncer gástrico avançado.
Wilson Shinjiro Matsuzaki, Francisco César Martins Rodrigues, Carlos Alberto Malheiros, Fares Rahal   +3 more
doaj   +1 more source

Synergisms of genome and metabolism stabilizing antitumor therapy (GMSAT) in human breast and colon cancer cell lines: a novel approach to screen for synergism

BMC Cancer, 2020
Background Despite an improvement of prognosis in breast and colon cancer, the outcome of the metastatic disease is still severe. Microevolution of cancer cells often leads to drug resistance and tumor-recurrence.
Jérôme Ruhnau, Jonas Parczyk, Kerstin Danker, Britta Eickholt, Andreas Klein   +4 more
doaj   +1 more source

Covalent disruptor of YAP-TEAD association suppresses defective Hippo signaling

eLife, 2022
The transcription factor TEAD, together with its coactivator YAP/TAZ, is a key transcriptional modulator of the Hippo pathway. Activation of TEAD transcription by YAP has been implicated in a number of malignancies, and this complex represents a ...
Mengyang Fan, Wenchao Lu, Jianwei Che, Nicholas P Kwiatkowski, Yang Gao, Hyuk-Soo Seo, Scott B Ficarro, Prafulla C Gokhale, Yao Liu, Ezekiel A Geffken, Jimit Lakhani, Kijun Song, Miljan Kuljanin, Wenzhi Ji, Jie Jiang, Zhixiang He, Jason Tse, Andrew S Boghossian, Matthew G Rees, Melissa M Ronan, Jennifer A Roth, Joseph D Mancias, Jarrod A Marto, Sirano Dhe-Paganon, Tinghu Zhang, Nathanael S Gray   +25 more
doaj   +1 more source

High-throughput approaches to discover novel immunomodulatory agents for cancer [PDF]

, 2013
The clinical success of immunomodulatory thalidomide derivatives has renewed the general interest in immunomodulatory anticancer compounds and prompted us to develop a high-throughput system to quantify immune effector-cell activity.
McMillin, Douglas William, Mitsiades, Constantine S   +1 more
core   +1 more source

Novel cyanine dye as competitive ligand for probing the drug–nucleic acid interactions

Біофізичний вісник, 2020
Background: During the past decades, increasing attention has been given to elucidating the molecular details of interactions between the pharmacological agents and nucleic acids since the drug–DNA complexation may lead to impairment of DNA replication ...
O. Zhytniakivska, U. Tarabara, A. Kurutos, A. Zabrudska, K. Vus, V. Trusova, G. Gorbenko, T. Deligeorgiev   +7 more
doaj   +1 more source

Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy

Neoplasia: An International Journal for Oncology Research, 2021
Blockade of the PD-1/PD-L1 immunologic checkpoint using monoclonal antibodies has provided breakthrough therapies against cancer in the recent years. Nevertheless, intrinsic disadvantages of therapeutic antibodies may limit their applications.
Fengling Wang, Wenling Ye, Shuang Wang, Yongxing He, Haiyang Zhong, Yuwei Wang, Yongchang Zhu, Jianting Han, Zhitong Bing, Shaoping Ji, Huanxiang Liu, Xiaojun Yao   +11 more
doaj   +1 more source